Zyus Life Sciences Corporation (TSE:ZYUS) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ZYUS Life Sciences Corporation, a Canadian life sciences firm, has been granted a U.S. patent for its novel cannabinoid-based pain management drug, Trichomylin® softgel capsules. This addition to ZYUS’ growing intellectual property portfolio marks a significant milestone in the company’s pursuit of non-opioid pain treatments. The patent represents the company’s commitment to innovation and the development of alternative therapies for pain management.
For further insights into TSE:ZYUS stock, check out TipRanks’ Stock Analysis page.